Publication date: 01/03/2018
CMAST and Rejuvenate Biomed are entering into a strategic partnership
The Belgian start-up company Rejuvenate Biomed, a spin-off from Janssen Pharmaceutica, researches the biology of ageing and wants to apply this knowledge to identify drugs that anticipate this process. The company aims to have its first clinical Proof of Concept product ready for divestment in 2020. As a partner, CMAST will offer strategic and scientific advice.
Through its virtual innovation and incubation (VIRTICUBE) platform, CMAST offers start-up companies support in areas such as writing their business plan, in looking for financing opportunities, and in connecting partners to carry out the research & development process.
Glenn Van Dael, CEO of CMAST: “The fight against ageing diseases such as dementia, Alzheimer’s disease, diabetes type II, ... is becoming a real challenge. We are getting older each day. Between 2000 and 2015, 30% more Belgians died associated with or as a result of such neurological diseases, as stated in the latest figures of the Belgian Agency of Care and Health. Most of these diseases will start at the age of 65. It would be a great step forward if we can extend this until the age of 85. At CMAST, we are driven by a passion to help shape the future of healthcare. Therefore, we strongly believe in this business case; and are happy to contribute to it.”
Ann Beliën, PhD, CEO of Rejuvenate Biomed: “We envision a future where people stay healthy for life. Thanks to the progress that has been made in the biology of ageing (geroscience), this has become an achievable goal. Our intrinsic capacity to cope with stressors at a cellular level decreases as we age. At Rejuvenate Biomed we are looking for ways to maintain this capacity for a longer period of time, thus delaying the start of these ageing diseases. We have been able to identify a number of products that have the potential to impact the ageing process. In 2019, we are planning to test our lead candidate in humans. We are very happy to have CMAST on board as a partner, sharing our passion and supporting us with complimentary advice”.
CMAST, with headquarters in Temse (Belgium), is a consultancy and project management company for the Healthcare and Life Sciences sector. Since the beginning of 2018 the company is part of The Adecco Group. CMAST employs more than 90 professionals, creating added value and innovation for its customers; in a sector that faces big challenges. Besides that CMAST brings together the right partners to develop innovative products and services.
CMAST was founded in 2008 and has branches in Belgium, Switzerland, Germany, Poland and the US.
More info on www.cmast.be
About Rejuvenate Biomed
Rejuvenate Biomed, an independent Belgium based R&D company and spin-out from Janssen Pharmaceutical companies of Johnson and Johnson, was established in October 2017. The company aims to increase the healthy years of life, also referred to as healthspan, by repositioning prescription drugs to the field of healthy ageing.
Rejuvenate Biomed had its seed investment secured in November 2017 to ensure funding for the first year, supporting the validation of the pharmacology platform and preparation for the clinical activities. Furthermore, Rejuvenate Biomed has joined the Johnson & Johnson Innovation JLINX community, a unique incubation and investment model designed to support emerging life science start-ups to turn transformational scientific ideas into commercial successes.
More info on www.rejuvenatebiomed.com